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Abstract
Background: Historically, only partial assessments of data quality have been performed in clinical trials, for which the most
common method of measuring database error rates has been to compare the case report form (CRF) to database entries
and count discrepancies. Importantly, errors arising from medical record abstraction and transcription are rarely evaluated
as part of such quality assessments. Electronic Data Capture (EDC) technology has had a further impact, as paper CRFs
typically leveraged for quality measurement are not used in EDC processes.
Methods and Principal Findings: The National Institute on Drug Abuse Treatment Clinical Trials Network has developed,
implemented, and evaluated methodology for holistically assessing data quality on EDC trials. We characterize the average
source-to-database error rate (14.3 errors per 10,000 fields) for the first year of use of the new evaluation method. This error
rate was significantly lower than the average of published error rates for source-to-database audits, and was similar to CRF-
to-database error rates reported in the published literature. We attribute this largely to an absence of medical record
abstraction on the trials we examined, and to an outpatient setting characterized by less acute patient conditions.
Conclusions: Historically, medical record abstraction is the most significant source of error by an order of magnitude, and
should be measured and managed during the course of clinical trials. Source-to-database error rates are highly dependent
on the amount of structured data collection in the clinical setting and on the complexity of the medical record,
dependencies that should be considered when developing data quality benchmarks.
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Introduction
Research sponsors and clinical research organizations (CROs)
are transitioning from paper-based data collection to electronic
data capture (EDC) systems. If novel technologies are to be
successfully integrated into clinical trials, their effects on data
quality must be fully understood. Relatively few new data
collection systems or methodologies, with the exception of
electronic patient reported outcomes (ePRO) [1–12], are well-
characterized with respect to data quality.
Data quality for paper-based clinical trials is traditionally assessed
through audits that compare database listings against data recorded
on paper case report forms (CRFs), thereby providing an estimate of
the database error rate [13,14]. Audits may also indicate location
and distribution of errors, which are usually categorized in a manner
meaningful to the study (e.g., critical versus noncritical) or the
organization (e.g., systematic versus random errors, or according to
root causes) [13]. In addition to providing objective information
about processes, audits can prevent future errors by identifying
problematic work patterns or behaviors.
Clinical trial data audits
There are numerous examples, both published [15–33] and
unpublished, of database audits that compare database listings to
CRFs. The average errorrate inthepublished literature for CRF-to-
database audits is 14 errors per 10,000 fields. Such audits do not
assess the percentage of correct data; rather, they identify additional
errors introduced during data processing [14]. Other errors,
including measurement error, recording error, or transcription
mistakes that occur when transferring data from source documents
to CRFs [34] lie outside the scope of traditional CRF-to-database
audits.Thus,thecommonly reported‘‘databaseerror rate’’ismerely
an estimate of errors introduced during data entry and cleaning; at
best equal to, but likely less than, the total ‘‘true’’ error rate.
Determiningactualdataqualityrequiresanassessmentofallpossible
sources of error, including data measurement, recording, abstrac-
tion, transcription, entry, coding, or cleaning [13,35].
In compliance with Good Clinical Practices (GCP), trial
sponsors typically perform source document verification (SDV)
of recorded data [36]. SDV compares original data, such as the
medical record, with the study CRF. Although the SDV process is
not usually quantified during trial operations, our literature review
identified 42 articles that provided source-to-database error rates,
primarily from registries [37–78]; the average error rate across
these publications was 976 errors per 10,000 fields. In contrast, the
average error rate for published CRF-to-database comparison
audits was 14 errors per 10,000 fields [15–33].
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leading to differences in data collection processes and resulting
data quality [79]. Although EDC proponents frequently claim that
clinical trial data quality improves with use of such systems, studies
supporting this contention have yet to appear in the peer-reviewed
literature, and it is not clear whether traditional methods of
ascertaining data quality suffice for EDC trials.
Exploring the effects of EDC on data quality
The comparison of published source-to-database and CRF-
to-database error rates suggests that most errors occur when data
are transferred from source to CRF during medical record
abstraction or transcription. Web-based EDC can only affect the
latter, through structured data collection, valid value lists, and on-
screen checks for values that are missing, out of range, or
inconsistent. Possible detrimental effects of EDC have not been
investigated.
We sought to explore the effects, if any, of EDC on data quality.
We hypothesized that for EDC to substantially improve quality, it
would have to facilitate improvements to the process of medical
record abstraction. Unfortunately, abstraction error rates are not
usually quantified in clinical trials. Manual SDV can detect
abstraction errors, but is labor intensive and highly sensitive to the
vagaries of locating the pertinent text or value in medical records,
leading to variability and measurement error. Additionally, ePRO
systems, in which data are directly entered by the research subject,
may be difficult or even impossible to assess for data quality
because the information may not be validly and reliably retrieved;
however, such issues lie outside the scope of our study.
Purpose
The National Institute on Drug Abuse (NIDA) Clinical Trials
Network (CTN) has instituted a process for quantifying data
quality on EDC trials. In 2005, the NIDA CTN implemented the
InForm (Phase Forward, Inc.) Web-based EDC system at the data
and statistical center (DSC) housed at the Duke Clinical Research
Institute. The system facilitates extensive error checking for
missing, out-of-range, and logically inconsistent values across the
CRF in real time so that many potential errors are caught prior to
final data submission.
NIDA CTN trials use structured paper data collection forms as
the source (patient questionnaire data for CTN trials are captured
via ePRO and are not included in our analysis). The data auditing
method for EDC trials provides an objective assessment of quality
at each site, including sample size calculations for audits,
assessment of data quality by site and by trial, corrective action
processes, and reports to communicate and monitor audit results.
We present findings from our initial evaluation of the NIDA CTN
data quality assessment program.
Methods
An audit plan was applied to trials conducted at the network’s
DSC that opened to enrollment after April 2005 and used Web-
based EDC, excluding trials that were migrated to the center. Two
audits, in which source data were compared to database listings for
a prespecified sample of study patients, were conducted at each
research site. The first source-to-database audit at each site
occurred at a point when 20%–30% of the expected subjects were
enrolled. The second audit was performed at 70%–80% of
expected enrollment. Our audit plan incorporated both the
statistically calculated sample sizes used in industry CRF-to-
database audits, and the National Cancer Institute’s method of
auditing cases source-to-database at each site.
Researchers have choices of powering the audit based by 1) the
widthof the confidenceinterval (CI),2)standarderror,or 3) a formal
hypothesis test. We considered CI and hypothesis testing methods of
sample size calculation. The first CI-based method is for comparison
of an error rate to a standard. Here, a known or assumed limit, or a
specified acceptance criterion (Formula 1) is compared to an
observed value. The intent is to ensure that the observed value is less
than some criterion; hence, a one-tailed interval. The second CI-
based method (Formula 2) is the CI for the difference between two
sites or times; i.e., based on the standard error of the difference. The
hypothesis-based method (Formula 3) is a comparison of two error
rates drawn from different samples to assess differences between sites
or times (e.g., error rates between two sites or between two different
time points within a site).
In the CI-based method, a one-sided CI might be used to assess
the probability that the rate is lower than some prescribed level.
Formula 2 would be employed to assess if a rate differed between
sites or times. Assuming a 95% CI, where npi.5, the CI can be
calculated from the following equations [80]:
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where Za is 1.645 (the one-sided alpha level associated with 95%
of the normal Z), and pi is the observed error rate in site, i, of
sample size ni. Further, in Formula 2, pj is the error at site or time j
of size nj to be compared to some other error rate pj with sample
size nj, and Za/2 is 1.96 (the two-sided alpha level associated with
95% of the normal Z). As written, the formulas show a CI for a
given pi (and pj) and sample size. The required sample size can
then be algebraically derived. Sample size curves for a variety of
desired CI widths and expected error rates are shown in Figure 1.
The sample size based on a one-sided CI for an acceptance
criterion of 50 errors per 10,000 fields, underlying expected error
rate of 30 errors per 10,000 fields, and a desired CI width of 20
errors per 10,000 fields, is 2100 fields. Curves for difference-based
CIs (Formula 2) can be similarly derived.
A formal hypothesis test could be conducted; e.g., to test if there
are differences between sites or times. The test of a difference in
error rates between two sites or times requires a slightly different
formula: pi and pj are averaged under the null hypothesis to give
Formula 3:
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The required sample size can then be algebraically derived at a
given error rate and assumed difference (pi and pi2pj). This test,
however, does not adjust for power, nor for multiple comparisons.
As shown in Figure 2, for a set of baseline error rates and assumed
differences, the sample size required to distinguish groups quickly
becomes large at 80% power. For example, if the error rate is 30/
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(difference=60), then at 80% power (and not adjusting the overall
type I error rate for multiple comparisons), we would require 2900
fields per group. Where nipi,5, the normal approximation breaks
down. Since many audits have found nipi,5, and since as nipi
increases, exact methods approach those using the normal
approximation, we employed the Clopper-Pearson exact method
[81] to calculate the CIs presented in the Results section.
Figure 1. Sample size curves: 95% confidence intervals (Formula 1), one-tailed. Intersection of vertical and horizontal lines shows sample
size needed to achieve a one-sided CI given an acceptance criterion of 50 errors per 10,000 data fields, an underlying expected error rate of 30 errors
per 10,000 fields, and a desired CI width of 20 errors per 10,000 fields (Fleiss J, Levin BL, Paik M. Statistical Methods for Rates and Proportions. 3
rd ed.
New York, NY: Wiley; 2003).
doi:10.1371/journal.pone.0003049.g001
Figure 2. Sample size curves: Hypothesis testing method (Formula 3) at 80% power and a of 0.05 (two-tailed), showing sample sizes
needed to distinguish among groups for given baseline error rates and assumed differences (Fleiss J, Levin BL, Paik M. Statistical
Methods for Rates and Proportions. 3
rd ed. New York, NY: Wiley; 2003).
doi:10.1371/journal.pone.0003049.g002
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norms (i.e., outpatient setting, patients whose conditions are
chronic rather than acute, and significant use of structured
worksheets for source data collection), we assumed a rate of 50
errors per 10,000 fields, and wished to obtain a 20 error per
10,000 field CI, yielding a sample size of 3400 fields per site.
A sample of at least 3500 data fields, providing 100 fields
overage, was obtained by selecting random forms (a CRF page or
subset of pages from a patient visit) from the list of patient forms.
An additional 3500 fields were audited when approximately 70%–
80% of expected enrollment was achieved, providing a statistically
representative sample at each site across two time points. Any
discrepancy between source and database not explained by study
documentation was counted as an error. The error rate
denominator was the number of fields actually audited, excluding
those defined as system-calculated or propagated fields.
Results
For our initial assessment, we completed source-to-database
audits of 24 sites participating in 4 EDC trials conducted through
the CTN (Figure 3). Preliminary findings show an average error
rate across all 4 trials of 14.3 errors per 10,000 fields, with a 95%
CI (averaged across audit CIs) of 12–39 per 10,000 fields, a low
rate compared with those reported for source-to-database audits,
and comparable to the average of reported CRF-to-database error
rates. Fourteen percent of errors were in fields critical to the
analysis (major independent or dependent variables or covariates).
Because these results, which were considerably lower than
published error rates for source-to-database audits, seemed
counterintuitive, we compared them to audit results from four
earlier paper-based trials managed at the DSC (Figure 4). Three
trials—5, 6, and 7—used paper CRFs sent to the DSC for double
data entry and cleaning. Trials 5, 6, and 7 had error rates of 3.4, 0,
and 3.7 errors per 10,000 fields, respectively, as determined by
CRF-to-database audits. Trial 5 used only CRF-to-database
auditing at the DSC. Trials 6 and 7 were migrated to the DSC
and audited both source-to-database (as part of ongoing quality
control) and CRF-to-database to measure processing fidelity for
migrated data. The source-to-database error rates for Trials 6 and
7 were 8.3 (5, 13) and 15.4 (13, 19) errors per 10,000 fields,
respectively (Figure 4).
Trial 8 was also migrated to the DSC but employed a form of
Web-based EDC in which sites completed paper CRFs and
transcribed data into the EDC system. Legacy data were single-
entered at the DSC from printed data listings and subjected to
‘‘CRF’’ (data listing)-to-database audits to assess fidelity of data
processing. The error rate for this migrated data was 20.3 (7, 50)
errors per 10,000 fields. The source-to-database error rate for
Trial 8 was 40.5 (36, 46) errors per 10,000 fields (Figure 4). We
attribute the difference between Trials 5, 6, and 7 as compared to
Trial 8 to the data processing method used for the latter trial.
Comparison of Figures 3 and 4 shows that the source-to-database
and CRF-to-database audit results are comparable.
During this period, the DSC also performed a source-to-
database audit for a trial in a different therapeutic area (epilepsy).
This study, characterized by medically complex patients, an
inpatient phase, and a more complex medical record, proved a
useful comparator to CTN protocol trials. Data were abstracted
Figure 3. Source-to-Database Audit Error Rates for CTN EDC Trials 1–4. The first source-to-database audit (‘‘early’’) was performed when
20%–30% of expected subject enrollment was reached; the second database audit (‘‘late’’) was performed when 70%–80% of expected enrollment
was reached.
doi:10.1371/journal.pone.0003049.g003
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fields from five subjects were audited. We identified 139 errors,
yielding an estimated error rate of 428 errors per 10,000 fields,
comparable to the published literature for source-to-database audits.
Discussion
The CTN source-to-database error rates were unexpectedly
low, especially when compared to the average of 976 errors per
10,000 fields derived from published reports for source-to-
database audits, and the rate of 428 errors per 10,000 fields from
a recent source-to-database audit conducted at our center. The
CTN source-to-database results more closely resembled CRF-to-
database error rates reported in the literature and touted by
industry.
Onereasonfortheseunexpectedresultsmaybetheprocessesused
to document treatment at NIDA CTN sites. CTN sites are
community treatment programs for substance abuse and addiction
treatment. In this setting, patient charts, largely consisting of clinic
notes, tend to be brief, and confidentiality policies restrict access to
research records. The CTN sites therefore separate subjects’
research and clinic records, with study visit documentation residing
in the research record. Because more data typically are collected
during clinical research than in standard practice, and because some
programsdonotclinicallydocumenttreatment,worksheetsprovided
to sites for capturing trial data often comprise the source documents.
Data from these worksheets are single-entered by site staff into an
EDC system with extensive on-screen checking.
In this context, our results are consistent with previous reports,
with CRF-to-database error rates being lowest, followed by EDC
data entered from worksheets, and finally the source-to-database
error rate from therapeutic areas characterized by more acute
patient conditions being highest. However, we emphasize that our
findings are derived from a specialized and somewhat atypical
clinical research environment; given the wide variability in the
design and conduct of clinical trials, our results may not be
generalizable to other research venues and should be viewed as
hypothesis-generating only.
We examined variations in local monitoring by regional and
community treatment centers, some of which undertake additional
quality assurance. Two trials employed a central quality assurance
(QA) monitor who performed SDV at all participating sites; one trial
required sites to have local QA auditors to perform SDV; another
neitherperformed central monitoring norrequired sitesto do so. We
expected pseudo-independent central monitoring to produce higher-
quality data than decentralized monitoring, and a decentralized
monitoring regime to produce higher-quality data than no
monitoring. However, we observed no correlation between database
error rates and differences inadditional local auditing ormonitoring.
In the clinical trials arena, source document verification (manual
comparison of the medical record to the CRF or database) although
unproven, is generally thought to decrease data errors. Effective
SDV would be a confounding factor impacting data error rates, and
should be taken into account when interpreting results.
Anticipation of an audit may be an important quality assurance
mechanism, providing sites an additional incentive to maintain data
quality. Based on observed error rates, one auditvisit per site may be
sufficient, as statistical power remains suffices for determining the
data quality of the trial as a whole as well as at each site.
Given these findings, the NIDA CTN changed its auditing plan
and decreased the frequency of audits, resulting in reduced travel
expenses incurred by auditors. Under the revised plan, an initial
source-to-database audit would be performed for each site upon
reaching 20%–30% of expected enrollment. Sites with an error
rate over 50 errors per 10,000 fields would require a second audit.
Most sites with error rates below this benchmark that also
addressed data queries and protocol violations in a timely manner
would not receive additional audits, although one site would be
chosen at random for a second audit. The revised plan results in
fewer logistical and financial burdens for sites, should continue to
provide comprehensive data quality monitoring, and could
potentially prove more cost-effective, although without accurate
comparators, this assertion remains speculative. An alternative
approach, in which sites would be given 24 hours to copy specified
charts and send them to the data center, was considered but
deemed more burdensome by the sites.
It is also worth noting that as electronic health records (EHRs)
become increasingly ubiquitous, clinical researchers may adopt
data collection strategies that directly access patient medical
records, which would streamline the process of data collection and
may significantly reduce errors associated with medical record
abstraction. Such strategies, however, will face a number of
hurdles, including electronic access to patient data by research
staff, information retrieval, privacy concerns, and issues relating to
data standardization.
Acceptance criteria
NIDA CTN sites initially requested that an acceptance criterion
be set in order to provide an objective performance standard;
however, the authors felt that the introduction of such a criterion
at the onset of the audit program was premature and not justified
by an appropriate basis in evidence. Instead, we compared sites
within a trial and performed an assessment, described here, early
in the program to investigate the applicability of a CTN-wide
acceptance criterion.
All random errors detected during source-to-database audits
were reviewed with the site and subsequently corrected. If an error
was deemed systematic (i.e., occurring across subjects or forms and
due to a common cause), the characteristics and root cause were
used to identify similar occurrences and apply corrections
throughout the database. Error rates within a trial were also
compared across sites to identify sites whose data quality differed
Figure 4. Source-to-database and CRF-to-database audits for
Comparator Trials 5–8. These audits were undertaken to provide a
‘‘control’’ for comparison with Trials 1–4 (results displayed in Figure 3).
doi:10.1371/journal.pone.0003049.g004
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audits for a given site was outside the bounds of the 95% CI
calculated over all audits on the trial, that site’s data quality was
deemed to differ sufficiently to warrant further investigation and
intervention. In such cases, site data were further examined to
elucidate the source of the errors, and corrective action was taken to
bring data quality within range of other sites. We also compared
error rates by trial to explore differences in data quality across trials.
Setting an acceptance criterion is unnecessary from a statistical
point of view, given that 95% CIs could be used. Two possibilities
then arise: 1) if any site’s error rate is above the upper bound of the
overall CI (aggregated across all sites, calculated from the total
number of audited fields across all sites and the total number of
errors across all sites for a trial), the error rate may be considered
excessive, or 2) ifany site’s CIexceeds the upperbound ofthe overall
CI, the site’s error rate would be considered excessive. However,
such rules may fail to produce operationally meaningful results; e.g.,
differences between sites might be so small as to have no effect on
conclusions drawn from the trial, if all sites had relatively low error
ratesand consistentlynarrow CIs.Suchmethodsmightalsopromote
a competitive or even punitive environment.
A useful acceptance criterion, then, would distinguish opera-
tionally meaningful differences. Now that we understand the
process capability of the CTN, naming an acceptance criterion
would also: 1) provide sites with objective performance bench-
marks, allowing sites to alter internal quality systems accordingly;
2) allow statisticians to assess its appropriateness for that particular
trial; and 3) provide a common language for trial-specific needs to
be communicated to sites.
The consistency of data from three of the 4 trials implies that a
‘‘network-wide’’ acceptance criterion could be set. CTN sites were
able to meet our relatively arbitrary limit of 50 errors or fewer per
10,000 fields; there was no indication that this limit was excessive.
Even though we measured source-to-database processes, it is
reassuring that this limit is within industry expectations for CRF-
to-database processes. A recent data quality survey conducted by
the Society for Clinical Data Management reported the most
popular overall database error rate acceptance criteria to be 50
errors per 10,000 fields and 10 errors per 10,000 fields. The most
popular acceptance criteria for critical variables were 10 errors per
10,000 fields and zero errors per 10,000 fields [34]. The question
of ‘‘how many errors is too many?’’ is difficult to answer because it
depends on many factors, including what variables are in error,
the robustness of the analysis, and the concern that a single data
error may cast doubt on the validity of the rest of the data [82].
Thus, arbitrary (and low) acceptance criteria tend to be employed.
We opted not to re-audit sites whose upper CIs exceeded our
established limit, thereby accepting the level of risk implicit within
the CI. However, in a situation in which many CTN sites were
participating in multiple trials, if a particular site consistently
appeared close to the limit of the acceptance criterion, those
findings could be addressed as a trend. During the initial program,
one trial had a significantly higher error rate than the others. A
single site was identified as the cause of the high error rate; that site
also had a significantly higher rate of protocol violations, and
suffered most frequently from computer-related problems.
Operationally, the initial 3500-field sample size allowed for a
half day on site, but the requirement to complete the audit at
20%–30% of enrollment at each site did not permit trips to be
combined. The benchmark of 20% enrollment was selected to
ensure that sufficient data were available for source-to-database
audits, but that the amount would be too large for sites to ‘‘scrub’’
the first few cases. Conducting audits sufficiently early for sites to
benefit from using results to prevent future problems and to allow
sufficient time for remediation were also significant considerations,
as such instant feedback appeared to promote more effective site
management.
Limitations
Our results are limited to a single therapeutic area and are
drawn from a setting that may not be generalizable to other
arenas. Our results, however, may not be extrapolable to
inexperienced research sites, or to therapeutic areas that require
significant amounts of medical record abstraction, or to industry
trials that lack CTN research infrastructure. Further, these results
are based on our experience with a single commercial EDC
system; use of a different system, or variations in implementation
of the same system, might have a significant impact on data
quality, and methods for calculating error rates vary widely across
the industry [13,34].
Important questions remain to be answered, however; for
example, the impact of data cleaning and auditing on trial results
remains unclear. In addition, a model does not yet exist for error
distributions in clinical trial data. In the absence of such a model,
event independence is assumed (e.g., in our sample size
calculations).
Conclusions
Our evaluation provides additional evidence that medical
record abstraction and transcription are the steps most likely to
introduce error into data collection and management processes,
and that source-to-database error rates may vary depending on
therapeutic area and according to site data practices. Data centers
should be aware of these factors, and provide assistance to sites in
reducing variability in the abstraction process. We also found that
the capacity to compare data at the level of individual sites
facilitated evaluation and allowed us to demonstrate the degree of
consistency among sites. Finally, we observed that higher error
rates may correlate with other operational problems. We believe
that objectively quantifying data quality will provide a more
comprehensive picture of a site’s performance.
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